Amphotericin B-deoxycholate is as effective and safe as the costly amphotericin B colloidal dispersion in the treatment of paediatric invasive fungal infections

Sarinah Tamring, Tey Ie Lane, Hani Syazwani Mohd Shah, Harikrishnan Shanmuganathan, Tzar Mohd Nizam Khaithir, Ahmad Nazrun Shuid, Boekhtiar Borhanuddin, Isa Naina Mohamed

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Amphotericin B deoxycholate (AmBD) and amphotericin B colloidal dispersion (AmBCD) are the two most commonly used antifungals for invasive fungal infections (IFI) among paediatric patients. The objective of this pilot study was to compare the efficacy, adverse effects and cost-effectiveness between AmBD and AmBCD in the treatment of IFI among paediatric patients admitted at Universiti Kebangsaan Malaysia Medical Centre (UKMMC). Methods: Secondary data analysis of the medical records of all paediatric patients with IFI was obtained and data extraction was performed for patients admitted between July 1, 2006 and June 30, 2011. Efficacy of treatment was determined and reports of adverse effects were noted. Results: Between July 1, 2006 and June 30, 2011, thirty-five patients received AmBD-only treatment and five patients received AmBCD-only treatment. Twenty-four patients were males and the mean age was 7.18 (SD 4.59) years. On average, the AmBCD treatment course was significantly more expensive than AmBD (p <0.01). Patients on AmBD had more adverse effects compared to those on AmBCD. However, there was no significant difference in severe adverse events between these groups. There was no significant difference in efficacy between these groups, in terms of IFI resolution or treatment duration. Conclusion: These findings imply that the use of AmBD instead of AmBCD in IFI treatment among paediatric patients is justified, given its cost-effectiveness, as there was no significant difference in the efficacy or in the incidence of severe adverse effects between these two treatments.

Original languageEnglish
Pages (from-to)228-237
Number of pages10
JournalJournal of Pharmacy and Nutrition Sciences
Volume4
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Amphotericin B
Pediatrics
secondary analysis
Therapeutics
costs
Malaysia
data analysis
Cost-Benefit Analysis
incidence
Group
Invasive Fungal Infections
deoxycholate drug combination amphotericin B
event
Medical Records
Incidence

Keywords

  • Amphotericin B
  • Amphotericin B colloidal dispersion
  • Amphotericin B deoxycholate
  • Antifungals
  • Liposomal amphotericin b
  • Paediatrics invasive fungal infections (IFI)

ASJC Scopus subject areas

  • Health(social science)
  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Amphotericin B-deoxycholate is as effective and safe as the costly amphotericin B colloidal dispersion in the treatment of paediatric invasive fungal infections. / Tamring, Sarinah; Lane, Tey Ie; Shah, Hani Syazwani Mohd; Shanmuganathan, Harikrishnan; Khaithir, Tzar Mohd Nizam; Shuid, Ahmad Nazrun; Borhanuddin, Boekhtiar; Naina Mohamed, Isa.

In: Journal of Pharmacy and Nutrition Sciences, Vol. 4, No. 4, 2014, p. 228-237.

Research output: Contribution to journalArticle

@article{798f47ac29604f018c338eabab9c4ec5,
title = "Amphotericin B-deoxycholate is as effective and safe as the costly amphotericin B colloidal dispersion in the treatment of paediatric invasive fungal infections",
abstract = "Amphotericin B deoxycholate (AmBD) and amphotericin B colloidal dispersion (AmBCD) are the two most commonly used antifungals for invasive fungal infections (IFI) among paediatric patients. The objective of this pilot study was to compare the efficacy, adverse effects and cost-effectiveness between AmBD and AmBCD in the treatment of IFI among paediatric patients admitted at Universiti Kebangsaan Malaysia Medical Centre (UKMMC). Methods: Secondary data analysis of the medical records of all paediatric patients with IFI was obtained and data extraction was performed for patients admitted between July 1, 2006 and June 30, 2011. Efficacy of treatment was determined and reports of adverse effects were noted. Results: Between July 1, 2006 and June 30, 2011, thirty-five patients received AmBD-only treatment and five patients received AmBCD-only treatment. Twenty-four patients were males and the mean age was 7.18 (SD 4.59) years. On average, the AmBCD treatment course was significantly more expensive than AmBD (p <0.01). Patients on AmBD had more adverse effects compared to those on AmBCD. However, there was no significant difference in severe adverse events between these groups. There was no significant difference in efficacy between these groups, in terms of IFI resolution or treatment duration. Conclusion: These findings imply that the use of AmBD instead of AmBCD in IFI treatment among paediatric patients is justified, given its cost-effectiveness, as there was no significant difference in the efficacy or in the incidence of severe adverse effects between these two treatments.",
keywords = "Amphotericin B, Amphotericin B colloidal dispersion, Amphotericin B deoxycholate, Antifungals, Liposomal amphotericin b, Paediatrics invasive fungal infections (IFI)",
author = "Sarinah Tamring and Lane, {Tey Ie} and Shah, {Hani Syazwani Mohd} and Harikrishnan Shanmuganathan and Khaithir, {Tzar Mohd Nizam} and Shuid, {Ahmad Nazrun} and Boekhtiar Borhanuddin and {Naina Mohamed}, Isa",
year = "2014",
doi = "10.6000/1927-5951.2014.04.04.1",
language = "English",
volume = "4",
pages = "228--237",
journal = "Journal of Pharmacy and Nutrition Sciences",
issn = "2223-3806",
publisher = "Lifescience Global",
number = "4",

}

TY - JOUR

T1 - Amphotericin B-deoxycholate is as effective and safe as the costly amphotericin B colloidal dispersion in the treatment of paediatric invasive fungal infections

AU - Tamring, Sarinah

AU - Lane, Tey Ie

AU - Shah, Hani Syazwani Mohd

AU - Shanmuganathan, Harikrishnan

AU - Khaithir, Tzar Mohd Nizam

AU - Shuid, Ahmad Nazrun

AU - Borhanuddin, Boekhtiar

AU - Naina Mohamed, Isa

PY - 2014

Y1 - 2014

N2 - Amphotericin B deoxycholate (AmBD) and amphotericin B colloidal dispersion (AmBCD) are the two most commonly used antifungals for invasive fungal infections (IFI) among paediatric patients. The objective of this pilot study was to compare the efficacy, adverse effects and cost-effectiveness between AmBD and AmBCD in the treatment of IFI among paediatric patients admitted at Universiti Kebangsaan Malaysia Medical Centre (UKMMC). Methods: Secondary data analysis of the medical records of all paediatric patients with IFI was obtained and data extraction was performed for patients admitted between July 1, 2006 and June 30, 2011. Efficacy of treatment was determined and reports of adverse effects were noted. Results: Between July 1, 2006 and June 30, 2011, thirty-five patients received AmBD-only treatment and five patients received AmBCD-only treatment. Twenty-four patients were males and the mean age was 7.18 (SD 4.59) years. On average, the AmBCD treatment course was significantly more expensive than AmBD (p <0.01). Patients on AmBD had more adverse effects compared to those on AmBCD. However, there was no significant difference in severe adverse events between these groups. There was no significant difference in efficacy between these groups, in terms of IFI resolution or treatment duration. Conclusion: These findings imply that the use of AmBD instead of AmBCD in IFI treatment among paediatric patients is justified, given its cost-effectiveness, as there was no significant difference in the efficacy or in the incidence of severe adverse effects between these two treatments.

AB - Amphotericin B deoxycholate (AmBD) and amphotericin B colloidal dispersion (AmBCD) are the two most commonly used antifungals for invasive fungal infections (IFI) among paediatric patients. The objective of this pilot study was to compare the efficacy, adverse effects and cost-effectiveness between AmBD and AmBCD in the treatment of IFI among paediatric patients admitted at Universiti Kebangsaan Malaysia Medical Centre (UKMMC). Methods: Secondary data analysis of the medical records of all paediatric patients with IFI was obtained and data extraction was performed for patients admitted between July 1, 2006 and June 30, 2011. Efficacy of treatment was determined and reports of adverse effects were noted. Results: Between July 1, 2006 and June 30, 2011, thirty-five patients received AmBD-only treatment and five patients received AmBCD-only treatment. Twenty-four patients were males and the mean age was 7.18 (SD 4.59) years. On average, the AmBCD treatment course was significantly more expensive than AmBD (p <0.01). Patients on AmBD had more adverse effects compared to those on AmBCD. However, there was no significant difference in severe adverse events between these groups. There was no significant difference in efficacy between these groups, in terms of IFI resolution or treatment duration. Conclusion: These findings imply that the use of AmBD instead of AmBCD in IFI treatment among paediatric patients is justified, given its cost-effectiveness, as there was no significant difference in the efficacy or in the incidence of severe adverse effects between these two treatments.

KW - Amphotericin B

KW - Amphotericin B colloidal dispersion

KW - Amphotericin B deoxycholate

KW - Antifungals

KW - Liposomal amphotericin b

KW - Paediatrics invasive fungal infections (IFI)

UR - http://www.scopus.com/inward/record.url?scp=84910611184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910611184&partnerID=8YFLogxK

U2 - 10.6000/1927-5951.2014.04.04.1

DO - 10.6000/1927-5951.2014.04.04.1

M3 - Article

AN - SCOPUS:84910611184

VL - 4

SP - 228

EP - 237

JO - Journal of Pharmacy and Nutrition Sciences

JF - Journal of Pharmacy and Nutrition Sciences

SN - 2223-3806

IS - 4

ER -